1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Priority Review Voucher Programs Poised For US Legislative Attention In 2020

 
• By Sue Sutter

Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.

Priority Fast Lane Sign Airport First Class Luxury Notification Blue Light
US FDA seeks statutory clarity on biologics eligible for priority review vouchers. • Source: Shutterstock

The US Food and Drug Administration’s priority review voucher programs appear poised for legislative attention this year, with the rare pediatric disease program due to sunset in September and the agency itself calling on Congress to clarify what types of biologic products are eligible for vouchers.

In addition, a recent Government Accountability Office report suggests potential legislative and regulatory changes across the voucher programs, which

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.